Business
TVG - milestone in development of COVID-19 vaccine
TVG - milestone in development of COVID-19 vaccine.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7929T\n Frontier IP Group plc\n 29 November 2021\n \n \n \n \n Reach - a non-regulatory announcement\n \n \n AIM: FIPP\n \n \n 29 November 2021\n \n \n \n \n \n Frontier IP Group Plc\n \n \n (\"Frontier IP\" or the \"Group\")\n \n \n \n \n \n \n \n \n Portfolio news - The Vaccine Group announces significant milestone in development of next generation COVID-19 vaccine\n \n \n \n \n \n \n \n \n \n \n \n Frontier IP, a specialist in commercialising intellectual property, notes the following announcement that portfolio company The Vaccine Group (\"TVG\" or the \"Company\") has achieved a significant milestone in the development of its next generation COVID-19 vaccine for use in humans. Frontier IP holds a 17 per cent equity stake in the Company. \n \n \n \n \n \n Neil Crabb, Frontier IP Chief Executive Officer, said\n : \"The first generation of COVID-19 vaccines have had a fantastic impact. However, COVID-19 is not going to disappear, so there is a need for a new generation of vaccines. There is a growing body of evidence to show that stimulating a T cell response confers longer-lasting immunity than other approaches and also offers the potential to provide protection against current and future variants of the disease.\"\n \n \n \n \n \n \n Jeremy Salt, Chief Executive of The Vaccine Group, said: \n \n \n \"These very strong trial results show that a COVID-19 vaccine based on our novel herpesvirus platform could prove to be extremely effective in mitigating the long-term impact of the disease. We are clearly excited about the potential for the vaccine.\" \n \n \n \n \n \n \n \n Simon Graham, Group Leader at The Pirbright Institute, said: \n \n \n \"Given the emerging data that strongly suggest an important role for cellular immunity in controlling SARS-CoV-2 infection, these are particularly promising results.\"\n \n \n \n \n \n \n \n \n \n The Vaccine Group statement begins: \n \n \n \n The Vaccine Group announces significant milestone in development of next generation \n \n \n COVID-19 vaccine\n \n \n · \n Trial data show strong T cell responses to SARS-CoV-2, as well as the more divergent SARS-CoV-1, demonstrating potential for broad immunity against current and\n \n future variants of the causal agent of COVID-19&n...